Last reviewed · How we verify

NCT05076864: LEFKIP

Levosimendans Pharmacokinetics in Intensive Care Patients. An Observational Study.

Status unknown Last updated 13 October 2021
What this trial tests

trial testing No intervention in Pharmacokinetics in 12 participants. Status unknown.

Timeline
1 January 2020
Primary endpoint
31 December 2025
31 December 2025

Quick facts

Lead sponsorKarolinska Institutet
StatusStatus unknown
Study typeOBSERVATIONAL
Enrollment12
Start date1 January 2020
Primary completion31 December 2025
Estimated completion31 December 2025
Sites1 location across Sweden

Drugs / interventions tested

Conditions studied

Sponsor

Karolinska Institutet

Who can join

18 and older, any sex, with Pharmacokinetics or Metabolites. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Evaluation of the pharmacokinetics of levosimendan and its metabolites in intensive care patients with normal, reduced and dialysis supported renal function.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other trials of No intervention

Trials testing the same drug.

Other recruiting trials for Pharmacokinetics

Currently open trials in the same condition.

Other Karolinska Institutet trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05076864.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing